Compare FLUX & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLUX | DYAI |
|---|---|---|
| Founded | N/A | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.4M | 29.9M |
| IPO Year | N/A | 2004 |
| Metric | FLUX | DYAI |
|---|---|---|
| Price | $1.51 | $0.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $6.00 | $3.00 |
| AVG Volume (30 Days) | ★ 219.4K | 64.5K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $63,484,000.00 | $3,342,195.00 |
| Revenue This Year | $0.18 | $12.52 |
| Revenue Next Year | $29.72 | $92.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.13 | N/A |
| 52 Week Low | $1.15 | $0.71 |
| 52 Week High | $7.55 | $1.73 |
| Indicator | FLUX | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 47.66 | 44.95 |
| Support Level | $1.40 | $0.85 |
| Resistance Level | $1.60 | $0.91 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 64.48 | 33.33 |
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.